Your browser doesn't support javascript.
loading
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration.
Zhao, Genshi; Green, Colin F; Hui, Yu-Hua; Prieto, Lourdes; Shepard, Robert; Dong, Sucai; Wang, Tao; Tan, Bo; Gong, Xueqian; Kays, Lisa; Johnson, Robert L; Wu, Wenjuan; Bhattachar, Shobha; Del Prado, Miriam; Gillig, James R; Fernandez, Maria-Carmen; Roth, Ken D; Buchanan, Sean; Kuo, Ming-Shang; Geeganage, Sandaruwan; Burkholder, Timothy P.
Affiliation
  • Zhao G; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana. Zhao_Genshi@Lilly.com.
  • Green CF; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Hui YH; Drug Disposition, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Prieto L; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Shepard R; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Dong S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Wang T; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Tan B; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Gong X; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Kays L; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Johnson RL; Toxicology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Wu W; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Bhattachar S; Product Design and Developability, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Del Prado M; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Gillig JR; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Fernandez MC; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Roth KD; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Buchanan S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Kuo MS; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Geeganage S; Cancer Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
  • Burkholder TP; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Mol Cancer Ther ; 16(12): 2677-2688, 2017 Dec.
Article in En | MEDLINE | ID: mdl-29054982
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytokines / Nicotinamide Phosphoribosyltransferase / Retinal Pigment Epithelium / Niacin Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytokines / Nicotinamide Phosphoribosyltransferase / Retinal Pigment Epithelium / Niacin Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2017 Document type: Article Country of publication: United States